Closing the PrEP access gap in Europe: a strategic framework for equity and innovation among difficult-to-reach populations


Por: Llibre, JM, Iniesta, C, Tittle, V, Clement, M, Rivero, A, Armenteros-Yeguas, I, Alvarez-López, P, Ryan, P, Arribas, JR and Moreno, S

Publicada: 1 mar 2026
Resumen:
HIV/AIDS remains a global health challenge with significant disparities in access to prevention strategies, particularly among underserved populations. Pre-exposure prophylaxis (PrEP) has proven to be an effective intervention in reducing HIV transmission, yet its uptake remains suboptimal in Europe. This report examines the current state of PrEP implementation in Spain, identifies key barriers to its access and proposes strategies for overcoming these obstacles, with a focus on equity and innovation. Despite PrEP being available since 2019, challenges such as centralized, hospital-based distribution, stigmatization, rigid eligibility criteria, excess medicalization and insufficient healthcare provider education persist. This study highlights the disproportionate underutilization of PrEP among populations with difficulty accessing prevention programmes, including women, migrants, sex workers, transgender individuals and people who inject drugs. Moreover, the introduction of long-acting injectables (LAI) and their endorsement by WHO represent a promising solution to improve PrEP efficacy, adherence and reduce the burden of frequent clinic visits. Drawing on successful international models, such as the 56 Dean Street clinic in London, this paper advocates for a decentralized, de-medicalized, community-based approach to PrEP delivery alongside policy reforms to simplify eligibility criteria and integrate PrEP into broader healthcare services. These solutions aim to address geographical and socio-cultural barriers, ultimately facilitating more equitable access to HIV prevention across Europe. The findings emphasize the importance of flexibility, community engagement and innovation to ensure that those most at need are ultimately offered PrEP, contributing to global efforts to close the HIV prevention gap.

Filiaciones:
:
 Univ Hosp Germans Trias I Pujol, Fight Infect Fdn, Infect Dis Div, Barcelona, Spain

 Ctr Invest Biomed Red Epidemiol & Salud Publ CIBER, Madrid, Spain

Iniesta, C:
 Spanish Interdisciplinary AIDS Soc SEISIDA, Madrid, Spain

 Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Infecciosas CIB, Madrid, Spain

Tittle, V:
 Chelsea & Westminster Hosp NHS Fdn Trust, 56 Dean St, London, England

Clement, M:
 Louisiana State Univ, Infect Dis, Hlth Sci Ctr, New Orleans, LA USA

Rivero, A:
 Univ Hosp Germans Trias I Pujol, Fight Infect Fdn, BCN Checkpoint Infect Dis Div, Barcelona, Spain

Armenteros-Yeguas, I:
 Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Infecciosas CIB, Madrid, Spain

 Hosp Clin San Carlos, Ctr Sanit Sandoval, Inst Invest Sanit San Carlos IdISSC, Madrid, Spain

Alvarez-López, P:
 Hosp Univ Vall DHebron, Unitat ITS VIH Drassanes Vall DHebron, Barcelona, Spain

Ryan, P:
 Spanish Interdisciplinary AIDS Soc SEISIDA, Madrid, Spain

 Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Infecciosas CIB, Madrid, Spain

 Univ Complutense Madrid, Hosp Univ Infanta Leonor, Fac Med, Dept Med, Madrid, Spain

 Soc Espanola Enfermedades Infecciosas & Microbiol, Grp Estudio Infecc Transmis Sexual GEITS, Madrid, Spain

Arribas, JR:
 Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Infecciosas CIB, Madrid, Spain

 Hosp Univ La Paz IDIPAZ, Serv Med Interna, Madrid, Spain

Moreno, S:
 Hosp Univ Ramon y Cajal, Serv Enfermedades Infecciosas, CIBERINFEC, IRYCIS, Madrid, Spain
ISSN: 03057453





Journal of Antimicrobial Chemotherapy
Editorial
Oxford University Press, GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND, Reino Unido
Tipo de documento: Review
Volumen: 81 Número: 3
Páginas:
WOS Id: 001690178000001
ID de PubMed: 41684246
imagen hybrid

MÉTRICAS